+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Orphan Drugs Global Market Report 2022: By Therapy, By Distribution, By Drug, By Disease

  • PDF Icon

    Report

  • 400 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553689
Orphan Drugs Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global orphan drugs market.



This report focuses on orphan drugs market which is experiencing strong growth. The report gives a guide to the orphan drugs market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the orphan drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Orphan Drugs market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider orphan drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
  • The orphan drugs market section of the report gives context. It compares the orphan drugs market with other segments of the orphan drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, orphan drugs indicators comparison

Scope


Markets Covered:


1) By Therapy Area: Oncology; Blood; Central Nervous System; Endocrine; Cardiovascular; Respiratory; Immunomodulatory
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Sales
3) By Drug Type: Biological; Non-Biological
4) By Diesease Type: Oncology; Hematology; Neurology; Cardiovascular; Others

Companies Mentioned: Bristol-Myers Squibb Company; Celgene Corporation; F. Hoffmann-La Roche Ltd; Amgen; Biogen

Countries: Brazil; China; France; Germany; India; Indonesia; Japan; South Korea; Russia; UK; USA; Australia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Frequently Asked Questions about the Global Orphan Drugs Market

What is the estimated value of the Global Orphan Drugs Market?

The Global Orphan Drugs Market was estimated to be valued at $154.81 billion in 2022.

What is the growth rate of the Global Orphan Drugs Market?

The growth rate of the Global Orphan Drugs Market is 10.4%, with an estimated value of $229.71 billion by 2026.

What is the forecasted size of the Global Orphan Drugs Market?

The Global Orphan Drugs Market is estimated to be worth $229.71 billion by 2026.

Who are the key companies in the Global Orphan Drugs Market?

Key companies in the Global Orphan Drugs Market include Bristol, Myers Squibb Company, Celgene Corporation, F.Hoffmann, La Roche Ltd., Amgen, Biogen, Bayer and GlaxoSmithKline plc..

Table of Contents

1. Executive Summary2. Orphan Drugs Market Characteristics3. Orphan Drugs Market Trends And Strategies4. Impact Of COVID-19 On Orphan Drugs
5. Orphan Drugs Market Size And Growth
5.1. Global Orphan Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Orphan Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Orphan Drugs Market Segmentation
6.1. Global Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oncology
  • Blood
  • Central Nervous System
  • Endocrine
  • Cardiovascular
  • Respiratory
  • Immunomodulatory
6.2. Global Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
6.3. Global Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Biological
  • Non-Biological
6.4. Global Orphan Drugs Market, Segmentation By Diesease Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

7. Orphan Drugs Market Regional And Country Analysis
7.1. Global Orphan Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Orphan Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Orphan Drugs Market
8.1. Asia-Pacific Orphan Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Orphan Drugs Market
9.1. China Orphan Drugs Market Overview
9.2. China Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Orphan Drugs Market
10.1. India Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Orphan Drugs Market
11.1. Japan Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Orphan Drugs Market
12.1. Australia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Orphan Drugs Market
13.1. Indonesia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Orphan Drugs Market
14.1. South Korea Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Orphan Drugs Market
15.1. Western Europe Orphan Drugs Market Overview
15.2. Western Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Orphan Drugs Market
16.1. UK Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Orphan Drugs Market
17.1. Germany Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Orphan Drugs Market
18.3. France Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Orphan Drugs Market
19.1. Eastern Europe Orphan Drugs Market Overview
19.2. Eastern Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Orphan Drugs Market
20.1. Russia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Orphan Drugs Market
21.1. North America Orphan Drugs Market Overview
21.2. North America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Orphan Drugs Market
22.1. USA Orphan Drugs Market Overview
22.2. USA Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Orphan Drugs Market
23.1. South America Orphan Drugs Market Overview
23.2. South America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Orphan Drugs Market
24.1. Brazil Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Orphan Drugs Market
25.1. Middle East Orphan Drugs Market Overview
25.2. Middle East Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Orphan Drugs Market
26.1. Africa Orphan Drugs Market Overview
26.2. Africa Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Orphan Drugs Market Competitive Landscape And Company Profiles
27.1. Orphan Drugs Market Competitive Landscape
27.2. Orphan Drugs Market Company Profiles
27.2.1. Bristol-Myers Squibb Company
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Celgene Corporation
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. F. Hoffmann-La Roche Ltd
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Amgen
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Biogen
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Orphan Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Orphan Drugs Market30. Orphan Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the orphan drugs market are Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Amgen, Biogen, Bayer, Novartis AG, GlaxoSmithKline plc., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Alexion Pharmaceuticals, Shire, Novo Nordisk, AstraZeneca, Eisai, Daiichi Sankyo, Merck, Teva Pharmaceutical Industries, Actelion Pharmaceuticals Ltd. and Aegerion Pharmaceuticals.

The global orphan drugs market is expected to grow from $140.40 billion in 2021 to $154.81 billion in 2022 at a compound annual growth rate (CAGR) of 10.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $229.71 billion in 2026 at a CAGR of 10.4%.

The orphan drugs market consists of sales of orphan drugs and related services that are used to treat rare diseases. An orphan drug is a pharmaceutical drug developed to treat patients suffering from rare diseases and would not make profit if developed commercially.

The main types of orphan drugs are biological and non-biological. The various therapy area include oncology, blood, central nervous system, endocrine, cardiovascular, respiratory and immunomodulatory use for the treatment of oncology, hematology, neurology, cardiovascular, and others. The study of blood and blood disorders is known as haematology. The drugs are distributed through hospital pharmacy, retail pharmacy and online sales.

North America was the largest region in the orphan drugs market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rising prevalence of rare diseases is a key factor driving the growth of the orphan drugs market. Any disease that affects a small percentage of the population is a rare disease. Rare disease treatments often require a cold chain, a supply chain regulated by temperature that is not readily accessible in all countries. Orphan diseases or rare diseases occurs rarely among the people (i.e. 7 out of 10,000). However, globally, the prevalence of rare diseases is increasing in recent years. According to the study published in European Journal of Human Genetics in 2019, there are 300 million cases of rare diseases and approximately 4% of total population is affected by rare disease at any point in time. Thus, the rising prevalence of rare diseases is driving the growth of the orphan drugs market.

Lack of supportive government policies hinders the orphan drugs market. Due to the lack of relevant policies for orphan drug, certain drugs do not receive any special recognition or priorities for approval by regulatory authority. Medgenome Labs Ltd., global research partner in accelerating insights into complex genetic diseases, pointed out that companies manufacturing orphan drugs frequently drop out in foreign markets due to a lack of government funding. For example, orphan medical products (OMPs) in India, due to lack of proper regulations and clear guidelines, do not obtain tax cuts or exemptions from customs duties. Therefore, lack of supportive government policies limits the growth of the orphan drugs market.

Approval of biological orphan drugs for multiple indication act as a key trend driving the growth of the orphan drugs market. The biological drugs are used for treating rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world. For Instance, in order to launch the company’s biological orphan drug development program Cardax, Inc. announced that it has been engaged with biological orphan drug expert Frederick D. Sancilio, Ph.D. For the development of commercial products, the companies are focused on obtaining biological orphan drugs to increase their revenue.

In November 2019, Bristol-Myers Squibb, a biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines, acquired Celgene for an undisclosed amount. Through this acquisition, Celgene shareholders received for each share, 1 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved. Celgene, a biopharmaceutical company positioned to address the needs of the patients with serious diseases.

The countries covered in the orphan drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F.Hoffmann-La Roche Ltd.
  • Amgen
  • Biogen
  • Bayer
  • Novartis AG
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • AbbVie inc.
  • Eli Lilly and Company
  • Alexion Pharmaceuticals
  • Shire
  • Novo Nordisk
  • AstraZeneca
  • Eisai
  • Daiichi Sankyo
  • Merck
  • Teva Pharmaceutical Industries
  • Actelion Pharmaceuticals Ltd.
  • Aegerion Pharmaceuticals

Methodology

Loading
LOADING...